

Feb 04 03 03:55p

Intervet Inc.

934 4305

p. 4

Attorney Docket Number O 98411 US

ABSTRACT OF THE DISCLOSURE


Please add new page 35 to the application containing the abstract of the disclosure as follows:

Attorney Docket Number O 98411 US

(35)

ABSTRACT OF THE DISCLOSURE

A serine protease inhibitor having the formula (I),



in which

J is H, R¹, R¹-O-C(O)-, R¹-C(O)-, R¹-SO₂-, R³OOC-(CHR²)_p-,
(R^{2a}, R^{2b})N-CO-(CHR²)_p- or Het-CO-(CHR²)_p-;


W is an amino-acid of the formula -NH-CHR¹-C(O)-,

-NR⁴-CH((CH₂)_qC(O)OR¹)-C(O)-,
-NR⁴-CH((CH₂)_qC(O)N(R^{2a}, R^{2b}))-C(O)-,
-NR⁴-CH((CH₂)_qC(O)Het)-C(O)-,

D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3

Piq, glutanyl or a (C₁-C₆) alkylester thereof;

E is -NR²-CH₂- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R¹ is selected from (1-12C)alkyl,

(2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF₃ or halogen, and from

(6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and

(14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl,

(3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;

R², R^{2a} and R^{2b} are each independently selected from

H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,

Attorney Docket Number O 98411 US

(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with
(3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with
(1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen; R³ is the same as R² or is Het-(1-6C)alkyl;
R⁴ is H or (1-3C)alkyl;
X and Y are CH or N, with the proviso that they are not both N;
Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S;
m is 1 or 2;
p is 1, 2 or 3;
q is 1, 2 or 3;
t is 2, 3 or 4;
or a pharmaceutically acceptable addition salt or solvate thereof.